RooLife itself isn't exactly flourishing. Shareprice 3c.Quote:
The company launched three new Tmall online stores in partnership with U.S. company Nuria Beauty, COLABDry Shampoo from the United Kingdom and New Zealand’s AFT Pharmaceuticals.
Printable View
RooLife itself isn't exactly flourishing. Shareprice 3c.Quote:
The company launched three new Tmall online stores in partnership with U.S. company Nuria Beauty, COLABDry Shampoo from the United Kingdom and New Zealand’s AFT Pharmaceuticals.
Singling out that the Nuria and Colab stores have gained traction with Chinese consumers, tends to imply that the AFT store hasn’t been such a success so far.. although it may just be that the other two have exceeded expectations.
Edit: Ignore that.. jumping to conclusions. AFT store was only launched in October.
AFT PHARMACEUTICALS (NZX: AFT) AND SETEK SIGN SUPPLY AGREEMENTAFT Pharmaceuticals (NZX; AFT, ASX; AFP) and medicinal cannabis company SETEKtoday announce an agreement which will see SETEK provide Good ManufacturingPractice (GMP) quality pharmaceutical-grade medicinal cannabis ingredients to AFT.It follows the two companies signing a memorandum of understanding (MOU) in October 2019 to work together in the research, development, and commercialisation of medicinal cannabis products.The agreement envisages AFT selling medicinal cannabis products into selected, markets starting with Australia and New Zealand. The timing of the launches of these products is confidential and will be advised at a later date.AFT Managing Director Hartley Atkinson said: “We are delighted to further advance our working relationship with SETEK to bring medicinal cannabis products to market.“SETEK’s international relationships and its understanding of medicinal cannabis markets both in New Zealand and offshore make it and ideal partner for AFT.“We have carefully studied the Australasian market and the required strategies to commercialise a new set of medicinal cannabis products.“This research has strengthened our view that these are a natural extension to the AFT product portfolio. They have the potential to benefit from our extensive distribution networks and to further strengthen AFT’s proposition with healthcare providers.SETEK Chief Executive David Pearce said AFT is uniquely placed to bring medicinal cannabis products to markets in New Zealand, Australia and further afield in markets where AFT already has distribution and licensing partners.“AFT’s understanding of pharmaceutical markets, the regulatory and commercial hurdles and its record of commercial success make it a leader in Australasia and an emerging player in the pharmaceutical market globally.“The next step of our business collaboration following on from the MOU has now been actioned with the signing of this agreement,” Mr Pearce said. Source: AFT Pharmaceuticals (NZX; AFT, ASX; AFP)
Wednesday 4th November 2020 Text too small?
More positive news from AFT as it takes steps towards the USA market..Full release here.
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has received a US Food and Drug Administration (FDA) complete response letter (CRL) covering its application for the approval of a tablet version of its Maxigesic® pain relief medication.
In the letter, the US regulator said an FDA Good Manufacturing Practice (GMP) inspection of the tablet production facilities – delayed due to COVID-19 related travel disruptions – was the “only deficiency” with AFT’s application.
A CRL indicates the FDA has completed its review of a new drug application. The letter covered AFT’s application for prescription Maxigesic tablets, branded Combogesic® in the US, for treatment of mild to moderate acute pain. The FDA also requested minor labelling changes and asked for updated global safety data.
AFT Managing Director Dr Hartley Atkinson said the CRL indicated AFT had cleared a significant hurdle on its path towards the commercialisation of the Maxigesic pain relief family of medicines in the world’s largest pharmaceutical market.
A positive update on the Maxigesic pain relief product - a further tick in FDA approval in the US.
https://www.nzx.com/announcements/362834
All these flurry of announcements makes me wonder if they softening us up for results time
...and it is typical of AFT to have frequent updates about their world domination plans which only shows how much they have going on!
I will be watching AFT's presentation on NZX Webinar at 2 pm on Wednesday.